Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage I bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-13 of 13 for your search:
Start Over
Transurethral Resection of Bladder Tumors Using PK Button Vaporization Electrode or Monopolar Loop Electrocautery in Treating Patients with Bladder Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 to 89
Trial IDs: WCI2119-11, NCI-2013-00065, IRB00053735, NCT01567462
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BOND 2 version 3.7, NCI-2015-01830, BOND 2 version 3.4, BOND 2 version 3.5, NCT02365818
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB4-845-02-IIIA, NCI-2015-01369, NCT02449239
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: BC001, NCI-2015-01102, 1R42CA171552-01, NCT02009332
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-14, NCI-2014-02463, NCT02138734
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Radiation Therapy and Cisplatin or Mitomycin and Fluorouracil in Treating Patients with Non-Muscle Invasive Stage I Bladder Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0926, NCI-2011-01974, 13-C-0175, CDR0000654727, PRTOG-0926_A05PAMDREVW01, NCT00981656
Dovitinib Lactate in Treating Patients With Refractory or Stage 0-I Bladder Cancer With FGFR3 Mutations or Overexpression
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU12-157, NCI-2013-00610, 1211009949, CTKI258AUS17T, NCT01732107
BCG Solution with or without PANVAC in Treating Patients with Localized Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 14-C-0036, NCI-2014-00115, 1310-1269, 140036, RD-13-X-04, 9539, NCT02015104
BCG Solution in Treating Patients with Non-muscle Invasive Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-174, NCI-2014-02528, NCT02281383
Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-057, NCI-2016-00312, 2014-004026-17, NCT02625961
Cabazitaxel, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with BCG solution-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM8506, NCI-2015-00757, NCT02202772
Observation or Immediate Surgery in Reducing Complications in Patients with Low Risk Bladder Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 50 and over
Trial IDs: VICC URO 15139, NCI-2016-00677, NCT02700724
Start Over